Φορτώνει......
A phase I study of nimotuzumab plus docetaxel in chemotherapy-refractory/resistant patients with advanced non-small-cell lung cancer
BACKGROUND: To determine the safety and therapeutic efficacy of nimotuzumab (h-R3) combined with docetaxel in advanced non-small-cell lung cancer (NSCLC) patients who have failed to respond to prior first-line chemotherapy. METHODS: In this single-center, open-label, dose-escalating phase I trial, p...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Chin J Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
AME Publishing Company
2016
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4779759/ https://ncbi.nlm.nih.gov/pubmed/27041923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.1000-9604.2016.02.07 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|